METHODS FOR TRIGGERING M1 MACROPHAGE POLARIZATION
The present disclosure relates to the field of nanomedicine, in particular for treating cancers. The present disclosure more specifically provides new methods of treating undesirable M2-polarized macrophages and/or inducing M1 macrophage polarization in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of nanoparticles containing metallic elements.
1 . A method of treating a condition associated with undesirable M2-polarized macrophages in a subject in need thereof, the method comprising administering nanoparticles containing metallic elements in a subject in need thereof,
wherein said nanoparticles have a mean hydrodynamic diameter below 10 nm.
2 . The method of claim 1 , wherein said nanoparticles containing metallic elements are administered to said subject in an amount sufficient for in vivo inducing M1 macrophage polarization.
3 . The method of claim 1 , wherein said metallic elements are cationic elements, either as oxide and/or chalcogenide or halide or as a complex with a chelating agent.
4 . The method of claim 1 , wherein said metallic elements are selected among the following elements: titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, zirconium, niobium, molybdenum, hafnium, tantalum, tungsten, lanthanum, yttrium, and any other lanthanides
5 . The method of claim 1 , wherein said metallic elements are selected among those suitable for use as T1 contrast agent in magnetic resonance imaging (MRI).
6 . The method of claim 1 , wherein said metallic elements are selected among high-Z elements.
7 . The method of claim 1 , wherein said condition associated with undesirable M2-polarized macrophages is cancer.
8 . The method of claim 1 , wherein said condition associated with undesirable M2-polarized macrophages is a cancer resistant or refractory to immunotherapies.
9 . The method of claim 8 , wherein said immunotherapeutic treatment comprises administering a therapeutically efficient amount of one or more immunotherapeutic drugs selected from the group consisting of anti-PD1, anti-PDL1 antibodies, (e.g. nivolumab, pembrolizumab, avelumab, durvalumab, cemiplimab, durvalumab or atezolizumab) and anti-CTLA-4 antibodies (e.g. ipilimumab).
10 . The method of claim 1 , wherein said method further comprises exposing said subject to a radiotherapy, wherein the combined effect of (i) said metallic element containing nanoparticles in inducing M1 macrophage polarization and (ii) said radiotherapy, produces a therapeutic effect on said cancer.
11 . The method of claim 1 , wherein said subject is not exposed to ionizing radiations for radiotherapy within a period of at least 7 days, following the administration of said nanoparticles containing metallic elements.
12 . The method of claim 1 , wherein said condition associated with undesirable M2-polarized macrophages is an inflammatory disorder, including progressive fibrotic diseases.
13 . The method of claim 1 , wherein said nanoparticles comprise
polyorganosiloxanes with a silicium weight ratio of at least 8% of the total weight of the nanoparticle,
chelates covalently bound to said polyorganosiloxane, in a proportion comprising between 5 and 100, and,
metallic elements complexed to the chelates.
14 . The method of claim 1 , wherein said nanoparticles comprises chelates for complexing the metallic elements, obtained by grafting one or more of the following chelating agents on said nanoparticles: DOTA, DTPA, EDTA, EGTA, BAPTA, NOTA, DOTAGA, and DTPABA, or their mixtures.
15 . The method of claim 1 , wherein said nanoparticles are gadolinium-chelated polysiloxane nanoparticles of the following formula
wherein PS is a matrix of polysiloxane and n is comprised between 5 and 50, and wherein the hydrodynamic diameter is comprised between 1 and 8 nm.
16 . The method of claim 1 wherein said nanoparticles have a mean hydrodynamic diameter between 1 and 8 nm.
17 . The method of claim 1 wherein said high-Z element is an element with an atomic Z number higher than 40.
18 . The method of claim 1 wherein said condition associated with undesirable M2-polarized macrophages is selected from the group consisting of cancer of head and neck, skin cancer, liver cancer, colon cancer, pancreatic cancer, breast cancer, ovary cancer, uterus cancer, cervical cancer, brain cancer, thyroid cancer, bladder cancer and renal cancer.
19 . The method of claim 1 , wherein said cancer said condition associated with undesirable M2-polarized macrophages is a cancer resistant or refractory to immunotherapies, and said method further comprises administering to said subject an immunotherapeutic treatment in combination with said metallic element containing nanoparticles.
20 . The method of claim 1 wherein said condition associated with undesirable M2-polarized macrophages is selected from the group consisting of idiopathic pulmonary fibrosis, hepatic fibrosis systemic sclerosis, allergy, asthma and atherosclerosis.